Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Net Margin: 2015-2025

Historic Net Margin for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to -332.97%.

  • Editas Medicine's Net Margin rose 10152932.00% to -332.97% in Q3 2025 from the same period last year, while for Sep 2025 it was -426.12%, marking a year-over-year decrease of 8518.00%. This contributed to the annual value of -733.71% for FY2024, which is 53963.00% down from last year.
  • Editas Medicine's Net Margin amounted to -332.97% in Q3 2025, which was up 76.86% from -1,438.71% recorded in Q2 2025.
  • Editas Medicine's Net Margin's 5-year high stood at -31.41% during Q4 2023, with a 5-year trough of -132,683.33% in Q3 2022.
  • For the 3-year period, Editas Medicine's Net Margin averaged around -11,526.91%, with its median value being -1,395.32% (2023).
  • In the last 5 years, Editas Medicine's Net Margin tumbled by 13,205,237bps in 2022 and then surged by 13,183,965bps in 2023.
  • Editas Medicine's Net Margin (Quarterly) stood at -332.30% in 2021, then slumped by 59,692bps to -929.22% in 2022, then soared by 89,782bps to -31.41% in 2023, then crashed by 11,691bps to -148.32% in 2024, then spiked by 10,152,932bps to -332.97% in 2025.
  • Its last three reported values are -332.97% in Q3 2025, -1,438.71% for Q2 2025, and -1,624.37% during Q1 2025.